argenx (ARGX) Price Target Increased to $182.00 by Analysts at Piper Jaffray Companies
argenx (NASDAQ:ARGX) had its target price raised by Piper Jaffray Companies from $161.00 to $182.00 in a research note issued to investors on Thursday, The Fly reports. The brokerage presently has an “overweight” rating on the stock. Piper Jaffray Companies’ target price would indicate a potential upside of 37.81% from the stock’s current price.
A number of other equities analysts have also weighed in on ARGX. Stifel Nicolaus reiterated a “buy” rating on shares of argenx in a report on Monday, February 4th. ValuEngine upgraded shares of argenx from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Guggenheim started coverage on shares of argenx in a report on Friday, February 22nd. They issued a “buy” rating and a $157.00 price objective on the stock. Wedbush boosted their price objective on shares of argenx from $131.00 to $144.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Finally, Zacks Investment Research lowered shares of argenx from a “hold” rating to a “sell” rating in a report on Tuesday, March 5th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $147.55.
Shares of ARGX opened at $132.07 on Thursday. The firm has a market capitalization of $4.30 billion, a price-to-earnings ratio of -56.20 and a beta of 1.12. argenx has a fifty-two week low of $63.81 and a fifty-two week high of $135.58.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.